title: Pharmacological evidence for the existence of a local renin-angiotensin system in porcine interlobar renal arteries.
abstract: 1. Changes in tension in response to cumulative additions of angiotensins (i.e., angiotensinogen, angiotensin I and angiotensin II), bradykinin and acetylcholine were monitored isometrically on ring preparations from porcine interlobar renal arteries. 2. Angiotensins consistently elicited contractile responses, whereas both bradykinin and acetylcholine produced relaxation of the arterial rings when active tone was induced by prostaglandin F2 alpha. 3. Contractile responses to angiotensin II could be completely blocked by the combined action of the cyclo-oxygenase inhibitor, indomethacin (1 microM) and the lipoxygenase inhibitor, nordihydroguairetic acid (NDGA, 10 microM). 4. Relaxant responses to bradykinin were unchanged during blockade of thromboxane A2 synthesis by dazoxiben (30 microM) and proved to be largely resistant to blockade by indomethacin (1 microM) and the prostaglandin I2 (prostacyclin) synthesis inhibitor, tranylcypromine (40 microM). 5. The angiotensin receptor blocker, saralasin (10 and 100 nM) antagonized responses to angiotensinogen, angiotensin I and angiotensin II effectively and with similar potency. Enalaprilic acid, the active metabolite of the converting enzyme inhibitor enalapril (300 nM), attenuated responses to angiotensin I but failed to inhibit those to angiotensinogen up to 1 microM. The serine protease kallikrein (0.001 to 1 mu ml-1) produced a dose-dependent shift to the left of the concentration-response curve for angiotensinogen. 6. It is suggested that the porcine interlobar renal artery possesses a local renin-angiotensin system with activatable angiotensin II forming enzyme(s) within the vessel wall.
authors.affiliation: Sandoz Pharma A.G., Basel, Switzerland.
authors.forename: E
authors.initials: E
authors.lastname: Müller-Schweinitzer
authors.forename: I
authors.initials: I
authors.lastname: Olea-Baza
mesh_terms: D000803:Angiotensin I / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000494:pharmacology; D000808:Angiotensinogen / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D015237:Dinoprost / Q000494:pharmacology; D004656:Enalapril / Q000494:pharmacology; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D007610:Kallikreins / Q000494:pharmacology; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D009637:Masoprocol / Q000494:pharmacology; D009126:Muscle Relaxation / Q000187:drug effects; D012077:Renal Artery / Q000187:drug effects*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D012504:Saralasin / Q000494:pharmacology; D013552:Swine; D014191:Tranylcypromine / Q000494:pharmacology
chemical_list: D000808:Angiotensinogen; D000804:Angiotensin II; D014191:Tranylcypromine; D004656:Enalapril; D009637:Masoprocol; D000803:Angiotensin I; D015237:Dinoprost; D007610:Kallikreins; D012504:Saralasin; D007213:Indomethacin